Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30245% above fair value
$4.68−0.03 (-0.53%)
Close on Nov 16, 2026Market cap $65.14MP/E –Yield –
Champions Oncology gross margin
Gross margin is gross profit as a percentage of revenue.
Champions Oncology's gross margin for the twelve months ending Jul 31, 2026 was 49.8%. For fiscal 2026 it was 48.0%, against 50.1% the year before. The highest annual figure on record is 51.9% in fiscal 2022.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | 48.0% | −2.1 |
| FY2025 | Apr 30, 2025 | 50.1% | +8.8 |
| FY2024 | Apr 30, 2024 | 41.4% | −3.8 |
| FY2023 | Apr 30, 2023 | 45.2% | −6.7 |
| FY2022 | Apr 30, 2022 | 51.9% | +4.1 |
| FY2021 | Apr 30, 2021 | 47.7% | +0.7 |
| FY2020 | Apr 30, 2020 | 47.1% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | 50.5% | +7.7 |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | 50.8% | +9.6 |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | 46.7% | −14.5 |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | 51.7% | +6.8 |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | 42.9% | −6.8 |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | 41.1% | −7.1 |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | 61.2% | +26.5 |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | 44.9% | +2.1 |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | 49.7% | +10.9 |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | 48.2% | +4.4 |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | 34.7% | −5.0 |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | 42.8% | −5.1 |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | 38.8% | −9.9 |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | 43.9% | −7.8 |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | 39.7% | −11.7 |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | 47.9% | −4.5 |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | 48.7% | −3.4 |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | 51.7% | +7.0 |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | 51.4% | −5.8 |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | 52.4% | +8.2 |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | 52.0% | +7.9 |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | 44.7% | +2.3 |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | 57.2% | +5.2 |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | 44.2% | −4.9 |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | 44.1% | −0.2 |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | 42.4% | −4.3 |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | 52.0% | +3.6 |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | 49.1% | −1.4 |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | 44.3% | −7.0 |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | 46.7% | −2.3 |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | 48.4% | +0.9 |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | 50.5% | – |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | 51.3% | – |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | 49.0% | – |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | 47.5% | – |
See a number that looks wrong?